United States Patent 12,290,529: Scope and Claims Analysis for Colon Cleansing Product with Split-Dose PEG/Sodium Sulfate Plus Acidifiers
United States Patent 12,290,529 claims a two-dose, multi-container colon cleansing composition built around PEG 3350 + sodium sulfate + potassium chloride + magnesium sulfate + sodium chloride, combined with malic acid and citric acid delivered as separate portions in additional containers, plus lemon-lime flavor, sucralose, and neotame, with a defined physiologic sodium balance limitation tied to performance in a subject.
What does US Patent 12,290,529 claim for a colon cleansing product?
Core claim structure (Claim 1): a colon cleansing kit/product comprising four containers that partition the formulation into:
- Dose 1, Portion A: PEG 3350 + sodium sulfate + potassium chloride + magnesium sulfate + sodium chloride (specific amounts)
- Dose 1, Portion B: malic acid + citric acid
- Dose 2, Portion A: the same PEG/electrolyte portion as Dose 1 Portion A (same specific amounts)
- Dose 2, Portion B: malic acid + citric acid
- Common formulation attributes: lemon-lime flavor, sucralose, neotame
- Performance limitation: the combination of Dose 1 + Dose 2 cleanses a colon without causing a sodium balance of −50.00 mEq/L or greater
Claim 1: element-by-element scope
1) “A first container … first portion of a first dose”
- PEG 3350: ~178.7 g
- Sodium sulfate: ~7.3 g
- Potassium chloride: ~1.12 g
- Magnesium sulfate: ~0.9 g
- Sodium chloride: ~0.5 g
2) “A second container … second portion of the first dose”
- Contains malic acid and citric acid (amounts locked in dependent Claim 2/3).
3) “A third container … first portion of a second dose”
- Same PEG/electrolyte amounts as in container 1.
4) “A fourth container … second portion of the second dose”
- Contains malic acid and citric acid.
5) Flavor and sweeteners
- lemon-lime flavor
- sucralose
- neotame
6) System performance / limitation
- “formulated so that” Dose 1 + Dose 2 cleanse a subject’s colon without causing a sodium balance of −50.00 mEq/L or greater.
This last phrase functions as an enforceable functional/efficacy limitation that can narrow infringement to products expected to achieve the claimed sodium balance outcome, even if the ingredients match.
Claim 1: how broad is the claim?
Claim 1 is broad in composition class (it claims a colon cleansing product) but narrow in operational definition because it requires:
- a multi-container delivery system (four containers)
- two-part dosing per dose day or dosing schedule (PEG/electrolytes split from acidifiers)
- exact quantities for PEG/electrolytes (by mass in grams)
- inclusion of specified flavoring and non-nutritive sweeteners
- a quantified sodium balance threshold tied to performance.
How do dependent claims limit malic acid and citric acid amounts?
Claim 2 scope (dependent on Claim 1)
Claim 2 narrows Claim 1 by specifying the acidifier amounts in the second portion of the first dose:
- Malic acid: ~1.43 g
- Citric acid: ~1.64 g
Claim 3 scope (dependent on Claim 1)
Claim 3 mirrors Claim 2 but specifies the acidifier amounts in the second portion of the second dose:
- Malic acid: ~1.43 g
- Citric acid: ~1.64 g
Practical effect for infringement mapping
A product could satisfy Claim 1’s container architecture and PEG/electrolyte amounts while still avoid Claims 2 and/or 3 if the malic/citric acid quantities differ from the claimed ~1.43 g and ~1.64 g in the respective second portions.
What is the likely claim “center of gravity”: formulation chemistry, packaging/dose partitioning, or the sodium balance limit?
Center of gravity appears to be “dose-partitioned delivery + performance sodium balance limitation.”
- The four-container split and “first portion/second portion” language is a clear mechanical boundary.
- The specified PEG/electrolyte mass locks the osmotic and electrolyte backbone.
- The acidifiers (malic/citric) are also locked in dependent claims, but independent Claim 1 requires their presence without exact amounts.
- The sodium balance limitation is the key functional restriction that can distinguish from prior art products with similar ingredients but different electrolyte/acidification and resulting sodium kinetics.
In enforcement terms
- A competitor with the same ingredients but different container partitioning or a different dosing kit structure may fall outside the claim.
- A competitor with the same kit structure and ingredients but failing the sodium balance outcome may face an argument against infringement based on the functional limit (“formulated so that … without causing … sodium balance”).
What prior art or adjacent product formats does this resemble (and where could it differ)?
Your claim set aligns with known colon cleansing paradigms that use PEG 3350 + electrolytes, sometimes paired with acidifying agents to influence pH and tolerability. The distinguishing features in this patent text are:
- Dose partitioning into separate acidifier containers
- Many commercial regimens combine components in one formulation or in fewer sachets.
- Here, PEG/electrolytes are separated from malic/citric acid in second portions delivered via separate containers for each dose.
- Measured electrolyte composition in the PEG portion
- PEG 3350 ~178.7 g and sodium sulfate ~7.3 g with explicit KCl, MgSO4, and NaCl masses constrain the formulation significantly.
- Flavor and sweeteners specified
- Lemon-lime flavor + sucralose + neotame is a strong product-identity anchor.
- Sodium balance performance constraint
- This is not a typical ingredient-only claim. It adds a quantitative physiologic endpoint.
Litigation relevance
In a validity challenge, examiners or challengers would typically focus on:
- whether prior art discloses the same split-dose/multi-container architecture,
- whether it discloses the same PEG/electrolyte mass configuration,
- whether it uses the same malic/citric acid amounts, and
- whether it reports sodium balance outcomes at or around the threshold.
How many distinct claim “design-arounds” exist based on the claim language?
Under Claim 1, design-arounds cluster into four categories:
A) Kit/packaging architecture changes (four-container constraint)
- Removing the “first/second/third/fourth container” structure or combining portions into fewer containers may avoid literal infringement.
B) PEG/electrolyte composition changes
- Even small deviations from the listed masses (within or beyond the “about” tolerance) can avoid Claim 1.
C) Acidifiers presence and amount
- Claim 1 requires malic acid + citric acid presence (without exact amounts).
- Claims 2 and 3 require specific quantities in both second portions.
D) Sodium balance threshold failure
- If a competitor’s regimen produces sodium balance ≤ −50.00 mEq/L (wording: “without causing a sodium balance of −50.00 mEq/L or greater”), it could still meet ingredient/kit constraints but contest infringement on the functional limit.
What is the likely strength profile for US 12,290,529?
Strength indicators (based on claim drafting)
- High specificity: exact PEG/electrolyte masses in grams.
- High specificity: malic/citric acid amounts in dependent claims.
- High specificity: flavor/sweeteners named.
- Functional narrowing: sodium balance threshold provides an additional legal boundary.
Potential weaknesses in enforcement
- Functional limitations (“formulated so that… without causing… sodium balance…”) can become evidence-heavy in litigation, requiring test results, protocol alignment, and expert interpretation.
- If competitors have substantially similar formulations but justify different sodium handling outcomes or interpret “about” ranges differently, infringement analysis may hinge on testing methodology.
How should a freedom-to-operate (FTO) team map infringement risk for Claim 1?
A product-by-product claim chart for Claim 1 should check, in order:
- Four-container structure with the two-part split per dose
- Dose count: first dose + second dose
- PEG/electrolyte mass in each “first portion” container
- Acidifier presence (malic acid + citric acid) in each “second portion” container
- Lemon-lime flavor + sucralose + neotame present
- Sodium balance outcome meeting the threshold (performance limitation)
A product that fails any one of these major elements is likely outside Claim 1 literal scope.
What is the practical competitive landscape this claim targets?
This patent reads like it targets colon cleansing products designed to:
- deliver electrolyte-balanced PEG-based cleansing,
- maintain tolerability via acidifiers and flavor/sweetener system,
- reduce risk of clinically relevant sodium imbalance as quantified by a sodium balance threshold.
Competitors most at risk are those marketing PEG/electrolyte regimens that match:
- the explicit electrolyte mass configuration,
- the malic/citric acid split-dose portioning,
- and the specific sensory additives (lemon-lime flavor, sucralose, neotame).
Key Takeaways
- US 12,290,529 Claim 1 covers a four-container, two-dose colon cleansing kit where each dose has a PEG/electrolyte “first portion” plus a malic/citric “second portion,” with lemon-lime flavor, sucralose, and neotame, and a functional sodium balance limitation.
- Claims 2 and 3 lock malic acid (~1.43 g) and citric acid (~1.64 g) for the second portions of both doses.
- The claim set is highly specific on formulation masses and packaging architecture, and it adds a quantified physiologic endpoint that can materially narrow both validity and infringement arguments.
FAQs
1) Does US 12,290,529 claim a one-dose product or a two-dose regimen?
Claim 1 requires a first dose and second dose, each split into a first portion and second portion delivered in separate containers.
2) What ingredients are mandatory for Claim 1 infringement?
At minimum: PEG 3350, sodium sulfate, potassium chloride, magnesium sulfate, sodium chloride, malic acid, citric acid, lemon-lime flavor, sucralose, and neotame, plus a four-container split.
3) Are the malic and citric acid quantities required in Claim 1?
No. Claim 1 requires malic acid and citric acid in the relevant containers, while the specific ~1.43 g and ~1.64 g amounts are required in dependent Claims 2 and 3.
4) What is the limiting performance parameter in Claim 1?
A colon cleansing formulation limitation tied to sodium balance, stated as “without causing a sodium balance of −50.00 mEq/L or greater.”
5) Which claim elements are most useful for designing around infringement?
Changing the multi-container partitioning, altering the PEG/electrolyte masses, altering acidifier amounts (to affect Claims 2/3), or targeting a formulation that disputes the sodium balance limitation.
References
- United States Patent No. 12,290,529 (claims provided by user).
